ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.26783
-0.79%
Brent Oil
79.345
-0.06%
Bitcoin
69,636.01
0.48%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Coya Therapeutics Inc (COYA)

  7. Coya Therapeutics Inc (COYA) Noticias

COYA

Coya Therapeutics (COYA)

Coya Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:COYA
FechaHoraFuenteTítuloSímboloCompañía
05/06/202419:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
05/06/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
03/06/202407:15Business WireCoya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in NeurologyNASDAQ:COYACoya Therapeutics Inc
28/05/202407:15Business WireCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexNASDAQ:COYACoya Therapeutics Inc
22/05/202407:15Business WireCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseNASDAQ:COYACoya Therapeutics Inc
20/05/202407:15Business WireCoya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)NASDAQ:COYACoya Therapeutics Inc
09/05/202415:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COYACoya Therapeutics Inc
09/05/202415:10Business WireCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
26/04/202407:15Business WireCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
22/04/202407:15Business WireCoya Therapeutics to Participate in the Mizuho Neuroscience SummitNASDAQ:COYACoya Therapeutics Inc
18/04/202407:15Business WireCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:COYACoya Therapeutics Inc
08/04/202407:15Business WireCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
19/03/202407:15Business WireCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
12/03/202408:00Business WireCoya Therapeutics to Participate in BTIG Fireside DiscussionNASDAQ:COYACoya Therapeutics Inc
12/03/202407:00Business WireCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
06/03/202407:15Business WireCoya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
29/02/202407:15Business WireCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
22/02/202407:15Business WireCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
21/02/202407:15Business WireCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”NASDAQ:COYACoya Therapeutics Inc
13/02/202407:15Business WireCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesNASDAQ:COYACoya Therapeutics Inc
29/01/202407:15Business WireCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
18/01/202407:15Business WireCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesNASDAQ:COYACoya Therapeutics Inc
16/01/202415:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COYACoya Therapeutics Inc
16/01/202407:15Business WireCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisNASDAQ:COYACoya Therapeutics Inc
16/01/202403:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:COYACoya Therapeutics Inc
05/01/202407:00Business WireCoya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)NASDAQ:COYACoya Therapeutics Inc
04/01/202415:46Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:COYACoya Therapeutics Inc
20/12/202308:46Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:COYACoya Therapeutics Inc
20/12/202307:30Business WireMr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.NASDAQ:COYACoya Therapeutics Inc
13/12/202307:00Business WireCoya Therapeutics’ CEO Dr. Howard Berman’s Letter to StockholdersNASDAQ:COYACoya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:COYA

Su Consulta Reciente

NYSE
MODG
Topgolf Callaway Brands
CREX
DEALTBTC
IdealGold
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados